Nitric oxide and coronary endothelial dysfunction in humans

Cardiovascular Research

Volumn 43, Issue 3, 1999, Pages 572-579

  Drexler, Helmut ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN;

ARTERIOSCLEROSIS; ARTERY ENDOTHELIUM; BIOSYNTHESIS; CARDIOVASCULAR FUNCTION; CORONARY ARTERY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; ENDOTHELIUM INJURY; HUMAN; HYPERCHOLESTEROLEMIA; MICROCIRCULATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; VASOMOTOR REFLEX;

EID: 0033566797     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(99)00152-2     Document Type: Review

References (72)

1. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 39:1997;287-324.
2. Weber C., Erl W., Weber K.C.S., Weber P.C. HMG-CoA Reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemiä J Am Coll Cardiol. 30:(5):1997;1212-1217.
3. Drexler H., Zeiher A.M., Wollschläger H., et al. Flow-dependent coronary artery dilatation in humans. Circulation. 80:1989;466-474.
4. Joannides R., Haefeli W.E., Linder L., et al. NO is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation. 91:1995;1314-1319.
5. Hornig B., Maier V., Drexler H. Physical training improves endothelial function in patients with chronic heart failure. Circulation. 93:1996;210-214.
6. Campbell D.J., Anastasopoulos F., Duncan A.M., et al. Effects of neutral converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. J Pharmacol Exp Ther. 287:(2):1998;567-577.
7. Baumgarten C.R., Linz W., Kunkel G., Schölkens B.A., Wiemer G. Ramiprilat increases bradykinin outflow isolated hearts of rat. Br J Pharmacol. 108:1993;293-295.
8. Groves P.H., Kurz S., Just H., Drexler H. The role of bradykinin in basal and flow-mediated endothelium-dependent vasodilation in the human coronary circulation. Circulation. 92:1995;3424-3430.
9. Mancini J.G.B., Henry G.C., Macaya C., et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation. 94:1996;258-265.
10. Hornig B., Kohler C., Drexler H. Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. Circulation. 95:1997;1115-1118.
11. Hornig B., Arakawa N., Haussmann D., Drexler H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation. 98:1998;2842-2848.
12. Vallance P., Collier J., Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 2:1989;997-1000.
13. Quyyumi A.A., Dakak N., Andrews N.P., et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 95:1995;1747-1755.
14. Drexler H., Zeiher A.M. Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolemia. Hypertension. 18:(suppl II):1991;II90-II99.
15. Reddy K.G., Nair R.N., Sheehan H.M., Hodgson J.B. Evidence that selective endothelial dysfunction may occur in the absence of angiografic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol. 23:1994;833-943.
16. Zeiher A.M., Drexler H., Wollschläger H., Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 83:1991;391-401.
17. Hausmann D., Johnson J.A., Sudhir K., et al. Angiographically silent atherosclerosis detected by intravascular ultrasound in patients with familial hypercholesterolemia and familial combined hyperlipidemia: Correlation with high density lipoproteins. J Am Coll Cardiol. 27:1996;1562-1570.
18. Chester A.H., O'Neil G.S., Moncada S., Tadjkarimi K., Yacoub M.H. Low basal and stimulated release of nitric oxide in atherosclerotic epicardial coronary arteries. Lancet. 336:1990;897-900.
19. Drexler H., Zeiher A.M., Meinzer K., Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet. 338:1991;1546-1550.
20. Creager M.A., Gallagher S.J., Girerd X.J., et al. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 90:1992;1248-1253.
21. Kuo L., Davis M.J., Cannon M.S., Chilian W.M. Pathophysiological consequences of atherosclerosis extend into the coronary microcirculation. Restoration of endothelium-dependent responses by L-arginine. Circ Res. 70:1992;465-476.
22. Zeiher A.M., Drexler H., Saurbier B., Just H. Endothelium-mediated coronary blood flow modulation in humans: effects of age, atherosclerosis, hypercholesterolemia, and hypertension. J Clin Invest. 92:1993;652-662.
23. Drexler H., Zeiher A.M., Köster W., Zeh W., Wieland H. Endothelial dysfunction in the coronary circulation in hypercholesterolemia: protective effect of high HDL-cholesterol (abstract). Circulation. 86:(suppl I):1992;I-117.
24. Tall A.R. Plasma high density lipoproteins. Metabolism and relationship to atherogenesis. J Clin Invest. 86:1990;379-384.
25. Heitzer T., Ylä-Herttuala S., Luoma J., et al. Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Circulation. 93:1996;1346-1353.
26. Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1991;1:93(9):1647-1650.
27. Murakami T., Mizuno S., Kaku B. Clinical morbidities in subjects with doppler-evaluated endothelial dysfunction of coronary artery. J Am Coll Cardiol. 2:1998;419A.
28. Pritchard K.A. Jr., Groszek L., Smalley D.M., et al. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ Res. 77:1995;510-518.
29. Tanner F.C., Noll G., Boulanger C.M., Lüscher T.F. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation. 83:1991;2012-2020.
30. Kikuta K., Sawamura T., Miwa S., Hashimoto N., Masaki T. High-affinity arginine transport of bovine aortic endothelial cells is impaired by lysophosphatidylcholine. Circ Res. 83:(11):1998;1088-1096.
31. Jay M.T., Chirico S., Siow R.C., et al. Modulation of vascular tone by low density lipoproteins: effects on L-arginine transport and nitric oxide synthesis. Exp Physiol. 82:(2):1997;349-360.
32. McDonald K.K., Zharikov S., Block E.R., Kilberg M.S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric oxide synthase may explain the 'arginine paradox'. J Biol Chem. 272:(50):1997;31213-31216.
33. Böger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction: Ist role in hypercholesterolemia. Circulation 1998, 3:98(18):1842-1847.
34. Pohl U., Herlan K., Huang A., Bassenge E. Nitric oxide mediated shear-induced dilation opposes myogenic vasoconstriction in small rabbit arteries. Am J Physiol. 261:1991;H2016-H2023.
35. Jones C.J.H., Kuo L., Davis M.J., Chilian W.M. Myogenic and flow-dependent control mechanisms in the coronary microcirculation. Basic Res Cardiol. 88:1993;2-10.
36. DeVita J.A., Treasure C.B., Yeung A.C., et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation. 85:1992;1390-1397.
37. Zeiher A.M., Drexler H., Wollschläger H., Saurbier B., Just H. Coronary vasomotion in response to sympathetic stimulation in humans: importance of the functional integrity of the endothelium. J Am Coll Cardiol. 14:1989;1181-1190.
38. Gordon J.B., Ganz P., Nabel E.G., et al. Atherosclerosis influences the vasomotor response of epicardial coronary arteries to exercise. J Clin Invest. 83:1989;1946-1952.
39. Yeung A.C., Vekshtein V.I., Krantz D.S., et al. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. New Engl J Med. 325:1991;1551-1556.
40. Gage J.E., Hess O.M., Murakami T., et al. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerine. Circulation. 73:1986;865-876.
41. VanderBerg E.K., Schmitz J.M., Benedict C.R., et al. Transcardiac serotonin concentration is increased in selected patients with limiting angina and complex coronary lesion morphology. Circulation. 79:1989;116-124.
42. Rubanyi G.M., Frye R.L., Holmes D.R. Jr., Vanhoutte P.M. Vasoconstrictor activity of coronary sinus plasma from patients with coronary artery disease. J Am Coll Cardiol. 9:1987;1243-1249.
43. Diodati J.G., Dakak N., Gilligan D.M., Quyyumi A.A. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation. 98:1998;17-24.
44. Golino P., Piscione F., Willerson J.T., et al. Divergent effects of serotonin on coronary artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. New Engl J Med. 324:(10):1991;641-648.
45. Langille B.L., O'Donnell F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science. 231:1986;405-407.
46. Lerman A., Holmes D.R. Jr., Bell M.R., et al. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation. 92:1995;2426-2431.
47. Lerman A., Edwards B.S., Hallett J.W., et al. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. New Engl J Med. 325:1991;997-1001.
48. DeVita J.A., Treasure C.B., Nabel E.G., et al. Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 81:1990;491-497.
49. Yasue H., Matsuyama K., Matsuyama K., et al. Responses of angiographically normal human coronary arteries to intracoronary injection of acetylcholine by age and segment. Possible role of early coronary atherosclerosis. Circulation. 81:1990;482-490.
50. Zeiher A.M., Schächinger V., Hohnloser S.H., Saurbier B., Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 89:1994;2525-2532.
51. Clarkson P., Celermajer D.S., Powe A.J., et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. 96:1997;3378-3383.
52. Leung W.H., Lau C.P., Wong C.K. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolaemic patients. Lancet. 341:1993;1496-1500.
53. Egashira K., Hirooka Y., Kai H., et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 89:1994;2519-2524.
54. Treasure C.B., Klein J.L., Weintraub W.S., et al. Beneficial effects of cholesterol lowering therapy on the coronary endothelium in patients with coronary artery disease. New Engl J Med. 332:1995;481-487.
55. Anderson T.J., Meredith I.T., Yeung A.C., et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. New Engl J Med. 332:1995;488-493.
56. Gould K.L., Martucci J.P., Goldberg D.I., et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation. 89:1994;1530-1538.
57. Andrews T.C., Raby K., Barry J., et al. Effect of cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation. 95:1997;324-328.
58. Van Boven A.J., Jukema W., Zwindermann A.H., et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation. 94:1996;1503-1505.
59. Aengevaren W.R.M., Uijen G.J.H., Jukema J.W., Bruschke A.V.G., Van der Werf T. Functional evaluation of lipid-lowering therapy By pravastatin in the regression growth evaluation statin study (REGRESS). Circulation. 96:1997;429-435.
60. Huggins G.S., Pasternak R.C., Alpert N.M., Fischman A.J., Gewirtz H. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation. 98:1998;1291-1296.
61. Brown G., Albers J.J., Fisher L.D., et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New Engl J Med. 323:(19):1990;1289-1298.
62. Laufs U., Fata V.L., Plutzky J., Liano J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
63. Griendling K.K., Minieri C.A., Ollerenshaw J.D., Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res. 74:1994;1141-1148.
64. Rajagopalan S., Kurz S., Münzel T., et al. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 97:1996;1916-1923.
65. Solzbach U., Hornig B., Jeserich M., Just H. Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation. 96:1979;1513-1519.
66. Schindler T.H., Nitzsche E., Jeserich M., et al. Ascorbic acid improves endothelial dysfunction in coronary microcirculation in hypertensive patients in 3 months follow-up (abstract). Circulation. Suppl:1998;I-175.
67. Lapenna D., DeGioia S., Ciofani G., et al. Glutathione-related antioxidant defenses in human atherosclerotic plaques. Circulation. 97:1998;1930-1934.
68. Kugiyama K. Intracoronary infusion of reduced glutathione improves endothelial vasomotor response to acetylcholine in human coronary circulation. Circulation. 97:1998;2299-2301.
69. DeVita J.A., Frei B., Holbrook M., et al. L-2-Oxothiazolidine-4-carboxylic acid reverse endothelial dysfunction in patients with coronary artery disease. J Clin Invest. 101:1998;1408-1414.
70. DeVita J.A., Keaney J.F. Jr., Raby K.E., et al. Low plasma ascorbic acid independently predicts the presence of an unstable coronary syndrome. J Am Coll Cardiol. 31:1998;980-986.
71. Heitzer T., Ylä-Herttuala S., Wild E., Luoma J., Drexler H. Effect of vitamin E on endothelial vasodilator function in patients with hypercholesterolemia, chronic smoking or both. J Am Coll Cardiol. 33:1999;499-505.
72. Anderson T.J., Uehata A., Garhard M.D., et al. Close relation of endothelial function in the human coronary peripheral circulations. J Am Coll Cardiol. 26:(5):1995;1235-1241.